Abstract
Abstract Pancreatic ductal adenocarcinoma (PDAC), also known as pancreatic ductal adenocarcinoma, is the most prevalent type of pancreatic tumor, predominantly impacting the exocrine portion of the pancreas. Individuals diagnosed with PDAC face a grim prognosis due to its highly malignant nature. By the year 2030, it is projected to emerge as the second leading cause of cancer-related fatalities. PDAC is known for its high degree of genomic instability. This review offers a summary of the frequently mutated genes in PDAC, as well as the morphological features, molecular profiles, available treatment options, and ongoing research in the field of PDAC.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
